| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
My research about organogenesis using ES, iPS cells has already been published. The present nephrology research included some issues (Tcf21, VEGF and kidney progenitors). A. Tcf21 expression and functional mechanism in glomerular podocytes of various kideny diseases: Tcf21 expression increased in podocytes of human and rat nephrotic syndrome, and then Tcf21 functionally influenced some cellular phenotypes in murine podocyte cell lone. B. Clinicopathology in VEGF inhibitor-associated kidney diseaes: VEGF inhibitors act to maintain glomerular capillaries, and the failure of this construction induced final glomerular damage. C. In vitro assays for murine nephrogenesis: The establishment of nephrogenesis assay system was continued, then some candidate tools were confirmed.
|
